No Data
No Data
No Data
No Data
No Data
Fewer Investors Than Expected Jumping On Qingdao Baheal Medical INC. (SZSE:301015)
With a price-to-earnings (or "P/E") ratio of 24.1x Qingdao Baheal Medical INC. (SZSE:301015) may be sending bullish signals at the moment, given that almost half of all companies in China have P/E rat
Simply Wall StApr 24 20:23 ET
Baiyang Pharmaceutical (301015.SZ): Plans to jointly invest in partnerships with professional investment institutions
Gelonghui, April 23 | Baiyang Pharmaceutical (301015.SZ) announced that the company collaborates with AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC Capital Operation Co., Ltd., Shandong New Kinetic Energy Fund Management Co., Ltd., Qingdao Innovation Investment Co., Ltd., Qingdao Hi-Tech Industry Development Parent Fund Partnership (Limited Partnership), Wuxi AstraZeneca CICC Venture Capital Partnership (Limited Partnership), Jinan Hi-Tech Finance Investment Co., Ltd., Yinfeng Finance (Beijing) Investment Management Co., Ltd., and Tianjin Jiashan Industrial Development Investment Co., Ltd. Invested in the establishment of AstraZeneca CICC
Gelonghui FinanceApr 23 07:28 ET
Baiyang Pharmaceutical (301015.SZ) plans to invest 50 million yuan in AstraZeneca CICC Qingdao Healthcare Venture Capital Fund to invest in the healthcare sector
Baiyang Pharmaceutical (301015.SZ) announced that the company, AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC...
Zhitong FinanceApr 23 06:29 ET
Baiyang Pharmaceutical (301015.SZ): 2023 net profit of 656 million yuan, plans to distribute 10 to 7.62 yuan
Gelonghui, April 22丨Baiyang Pharmaceutical (301015.SZ) announced its 2023 annual report. Operating income for the reporting period was 7.564 billion yuan, up 0.72% year on year; net profit attributable to shareholders of listed companies was 656 million yuan, up 29.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 635 million yuan, up 25.14% year on year; basic income per share was 1.25 yuan; it plans to pay a cash dividend of 7.62 yuan (tax included) for every 10 shares to all shareholders.
Gelonghui FinanceApr 22 04:37 ET
Qingdao Baheal Medical (SZSE:301015) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Simply Wall StMar 28 19:03 ET
Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.
The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities
Zhitong FinanceMar 26 23:24 ET
No Data
No Data